뉴스벤징가
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
· 발표
기사 요약
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…